Comparing taletrectinib to standard therapy for ROS1-positive lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that has spread or come back.
- Your tumor has a specific genetic change called ROS1 rearrangement (confirmed by a test).
- You have at least one tumor that can be measured on scans.
- You are 18 years or older (or 20 in some countries).
- You are in generally good health (able to do most daily activities).
- You have not had any prior targeted therapy (TKI) or immunotherapy for advanced lung cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study gathers real-world experience with the targeted drug taletrectinib for people with a specific type of advanced lung cancer (ROS1-positive) that has spread to the brain. Participation may help doctors better understand how well the drug works in everyday practice.
This study follows people with advanced ROS1-positive non-small cell lung cancer who are taking targeted therapy. It aims to understand how well the treatment works in real life and is for those who haven't had any prior treatment for their lung cancer.
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
This trial compares a new targeted pill (SY-3505) to the current standard drug (crizotinib) as a first treatment for people with advanced ALK-positive non-small cell lung cancer (NSCLC). It aims to find out which drug works better and has fewer side effects.
This study tests whether adding focused radiation to a targeted cancer pill works better than the pill by itself. It is for people with advanced non-small cell lung cancer (NSCLC) whose tumor has an EGFR or ALK/ROS driver mutation and who have not gotten worse after starting the targeted pill.
This study tests three different targeted pills (osimertinib, afatinib, dacomitinib) in people with advanced EGFR-mutated lung cancer who haven't had targeted therapy before. The goal is to find which pill works best and has the fewest side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.